<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092872</url>
  </required_header>
  <id_info>
    <org_study_id>0557-012</org_study_id>
    <secondary_id>MK0557-012</secondary_id>
    <secondary_id>2004_031</secondary_id>
    <nct_id>NCT00092872</nct_id>
  </id_info>
  <brief_title>A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 1-year study to assess the safety, tolerability, and efficacy of an investigational
      drug in obese patients after a very low calorie diet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight after 1 year of treatment.</measure>
    <time_frame>After 1 year of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability.</measure>
    <time_frame>After 1 year of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference; Blood pressure, body fat mass, biochemical markers (fasting plasma, lipid profile, fasting plasma glucose, leptin, insulin, insulin sensitivity); body weight after 2 years</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">359</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0557</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese men and nonpregnant women between the ages of 18 and 65 years with a body mass
             index (height to weight ratio) as required by the study.

        Exclusion Criteria:

          -  Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood
             sugar)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82.</citation>
    <PMID>17011500</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

